NCT07265284

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

A Phase Ⅰ/Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Picankibart in Adolescent Patients With Moderate to Severe Plaque Psoriasis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 104 (estimated)
• Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Industry
• Sex: All
• Age: 12 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	IBI112	IBI112 by subcutaneous injection
DRUG	placebo	placebo by subcutaneous injection

Timeline

• Start date: 2025-12-03
• Primary completion: 2026-09-30
• Completion: 2029-01-31
• First posted: 2025-12-04
• Last updated: 2025-12-22

Locations

1 site across 1 country: China